Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by AMI Asset Management Corp

AMI Asset Management Corp trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,390 shares of the biopharmaceutical company’s stock after selling 5,665 shares during the period. AMI Asset Management Corp owned about 0.11% of Halozyme Therapeutics worth $5,589,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HALO. Rise Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter worth $25,000. Principal Securities Inc. acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth $34,000. First Horizon Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares in the last quarter. Parkside Financial Bank & Trust acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth $64,000. Finally, Headlands Technologies LLC lifted its position in shares of Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 1,613 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HALO. JMP Securities reduced their target price on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of Halozyme Therapeutics in a research note on Monday, June 24th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. Finally, Benchmark lifted their price target on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $57.25.

Halozyme Therapeutics Stock Performance

HALO stock traded up $0.71 during trading on Thursday, hitting $52.01. 839,272 shares of the company’s stock traded hands, compared to its average volume of 1,563,506. The company has a quick ratio of 5.36, a current ratio of 6.64 and a debt-to-equity ratio of 8.44. Halozyme Therapeutics, Inc. has a 52 week low of $32.83 and a 52 week high of $53.22. The stock has a fifty day moving average price of $46.08 and a two-hundred day moving average price of $40.71. The stock has a market capitalization of $6.62 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 0.52 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The firm had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $51.93, for a total transaction of $519,300.00. Following the completion of the transaction, the chief financial officer now owns 15,480 shares in the company, valued at $803,876.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 40,000 shares of company stock worth $1,858,100. Insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.